Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 1:25 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 673–696 of 1,618 matching trials from the live ClinicalTrials.gov search.
Conditions
Geographic Atrophy
Interventions
ACU-4429, Placebo
Drug
Lead sponsor
Kubota Vision Inc.
Industry
Eligibility
55 Years and older
Enrollment
508 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Phoenix, Arizona
Conditions
Choroidal Neovascularization
Interventions
Imatinib Mesylate /Ranibizumab
Drug
Lead sponsor
Vitreous -Retina- Macula Consultants of New York
Other
Eligibility
51 Years and older
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2006
U.S. locations
1
States / cities
New York, New York
Conditions
Retinitis Pigmentosa
Interventions
Electro-acupuncture
Procedure
Lead sponsor
Johns Hopkins University
Other
Eligibility
10 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Baltimore, Maryland
Conditions
Stargardt's Macular Dystrophy
Interventions
avacincaptad pegol, Sham
Drug
Lead sponsor
Astellas Pharma Global Development, Inc.
Industry
Eligibility
18 Years to 60 Years
Enrollment
121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
17
States / cities
Phoenix, Arizona • Los Angeles, California • Gainesville, Florida + 14 more
Conditions
Ocular Melanoma
Interventions
Not listed
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2017
U.S. locations
1
States / cities
Los Angeles, California
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Alpha Lipoic Acid in Geographic Atrophy

NCT02613572
Conditions
Age-Related Macular Degeneration
Interventions
alpha lipoic acid, Placebo
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
55 Years to 90 Years
Enrollment
68 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2019
U.S. locations
5
States / cities
Iowa City, Iowa • Teaneck, New Jersey • Eugene, Oregon + 2 more
Conditions
LCA5
Interventions
AAV8.hLCA5
Biological
Lead sponsor
Opus Genetics, Inc
Industry
Eligibility
4 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
2
States / cities
Philadelphia, Pennsylvania • Dallas, Texas
Conditions
Mild Cognitive Impairment
Interventions
BBH-1001 Brain Health Supplement, Lifestyle Intervention, Brain Health Placebo
Dietary Supplement · Other
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
55 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Los Angeles, California
Conditions
Cataract, Retinal Edema, Inflammation
Interventions
Prolensa (bromfenac 0.07%), Ilevro (nepafenac 0.3%)
Drug
Lead sponsor
Melissa Toyos
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
1
States / cities
Nashville, Tennessee
Conditions
Visual Acuity, Geographic Atrophy, Macular Degeneration
Interventions
CNTO 2476 3.0 x 10^5 cells, Subretinal Delivery System
Drug · Device
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
55 Years to 90 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
8
States / cities
Arcadia, California • Chicago, Illinois • Lexington, Kentucky + 5 more
Conditions
Alzheimer Disease
Interventions
AMDX-2011P
Drug
Lead sponsor
Amydis Inc.
Industry
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Phoenix, Arizona
Not yet recruiting Phase 4 Interventional

Rocklatan Retinal Perfusion OCT Study

NCT07174401
Conditions
Glaucoma
Interventions
Rocklatan eye drops will be instilled nightly in one eye diagnosed with glaucoma for up to 12 months., Two optical coherence tomography (OCT) devices will be used to assess blood flow changes.
Drug · Device
Lead sponsor
Oregon Health and Science University
Other
Eligibility
21 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Portland, Oregon
Conditions
Telangiectasia
Interventions
Ranibizumab
Drug
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
18 Years to 80 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Age Related Macular Degeneration, Diabetic Macular Edema, Retinal Vein Occlusion
Interventions
Varying needle size with intravitreal ranibizumab or aflibercept
Procedure
Lead sponsor
Wills Eye
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Retinitis Pigmentosa, Usher Syndrome Type 2, Deaf Blind, Retinal Disease, Eye Diseases, Eye Diseases, Hereditary, Eye Disorders Congenital, Vision Disorders
Interventions
QR-421a, Sham-procedure
Drug · Other
Lead sponsor
Laboratoires Thea
Industry
Eligibility
12 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
2
States / cities
Dallas, Texas • Madison, Wisconsin
Completed Not applicable Interventional Accepts healthy volunteers

Study to Compare the Diopsys NOVA and LKC RETeval Devices

NCT05416268
Conditions
Retinal Disease
Interventions
Electroretinography
Diagnostic Test
Lead sponsor
Diopsys, Inc.
Industry
Eligibility
22 Years and older
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Tahlequah, Oklahoma
Conditions
Deafness, Kidney Diseases, Kidney Neoplasms, Neoplasms, Retinal Diseases
Interventions
Not listed
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
Not listed
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2000
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Macular Edema, Diabetic
Interventions
Ranibizumab, Placebo, PF-04634817, Masked Sham Therapy
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
199 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
33
States / cities
Phoenix, Arizona • Tucson, Arizona • Arcadia, California + 25 more
Conditions
Cytomegalovirus Retinitis, HIV Infections
Interventions
Ganciclovir
Drug
Lead sponsor
Roche Global Development
Other
Eligibility
3 Months to 12 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
8
States / cities
Birmingham, Alabama • Los Angeles, California • Chicago, Illinois + 3 more
Conditions
Retinoblastoma
Interventions
vincristine, topotecan, filgrastim, PEG-filgrastim, carboplatin, focal therapy, etoposide, cyclophosphamide, MESNA, doxorubicin, enucleation, external beam radiation or proton beam radiation
Drug · Other · Procedure + 1 more
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
Not listed
Enrollment
174 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2027
U.S. locations
1
States / cities
Memphis, Tennessee
Conditions
Diabetic Retinopathy, NPDR - Non Proliferative Diabetic Retinopathy
Interventions
VX-01, Placebo
Drug
Lead sponsor
Vantage Biosciences Ltd
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
9
States / cities
Beverly Hills, California • Palo Alto, California • Santa Barbara, California + 6 more
Conditions
Ewing's Sarcoma, Osteosarcoma, Astrocytoma, Atypical Teratoid/Rhabdoid Tumor, Ependymoma, Germ Cell Tumor, Glioma, Medulloblastoma, Rhabdoid Tumor, Retinoblastoma, Clear Cell Sarcoma, Renal Cell Carcinoma, Wilms Tumor, Hepatoblastoma, Neuroblastoma, Rhabdomyosarcoma
Interventions
sirolimus
Drug
Lead sponsor
Emory University
Other
Eligibility
Up to 30 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
1
States / cities
Atlanta, Georgia
Not listed Phase 2 Interventional Accepts healthy volunteers

PST/Laser v. Laser Alone for CSME

NCT00229918
Conditions
Diabetic Retinopathy
Interventions
triamcinolone acetonide
Drug
Lead sponsor
Edward Hines Jr. VA Hospital
Federal
Eligibility
25 Years to 80 Years · Male only
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2006
U.S. locations
1
States / cities
Hines, Illinois
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Ocular Proteomics Testing In Chronic Atrophy

NCT07298291
Conditions
Age-Related (Dry) Macular Degeneration
Interventions
AC Tap (anterior chamber paracenthesis)
Procedure
Lead sponsor
ClinOmicsAI
Network
Eligibility
50 Years to 89 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Erie, Pennsylvania